Furo[3,2-c]Pyridine and Thieno[3,2-c]pyridine compounds of Formula I, and pharmaceutically acceptable salts thereof, preparation, intermediates, pharmaceutical compositions, and use, such as in disease treatment, including cancers, including conditions in which EMT is involved, including conditions mediated by protein kinase activity such as RON and/or MET.
本发明涉及Furo[3,2-c]
吡啶和Thieno[3,2-c]
吡啶化合物(I式),以及其制备、中间体、制药组合物和用途,例如在疾病治疗中使用,包括癌症,包括涉及
EMT的情况,包括由蛋白激酶活性介导的情况,例如RON和/或MET。其中,所述化合物的药学上可接受的盐也包括在内。